Literature DB >> 25232572

Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy.

Paul Moayyedi1, John K Marshall, Yuhong Yuan, Richard Hunt.   

Abstract

Mesh:

Year:  2014        PMID: 25232572      PMCID: PMC4071888          DOI: 10.1155/2014/346590

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


× No keyword cloud information.
  33 in total

1.  Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis.

Authors:  Chun Shing Kwok; Aaron Kobina Arthur; Chukwudubem Ifeanyichukwu Anibueze; Sonal Singh; Rodrigo Cavallazzi; Yoon Kong Loke
Journal:  Am J Gastroenterol       Date:  2012-04-24       Impact factor: 10.864

2.  Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis.

Authors:  Sailajah Janarthanan; Ivo Ditah; Douglas G Adler; Murray N Ehrinpreis
Journal:  Am J Gastroenterol       Date:  2012-06-19       Impact factor: 10.864

3.  How much do PPIs contribute to C. difficile infections?

Authors:  Grigorios I Leontiadis; Mark A Miller; Colin W Howden
Journal:  Am J Gastroenterol       Date:  2012-07       Impact factor: 10.864

4.  Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection.

Authors:  Matthew J Hamilton; Alexa R Weingarden; Michael J Sadowsky; Alexander Khoruts
Journal:  Am J Gastroenterol       Date:  2012-01-31       Impact factor: 10.864

5.  Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.

Authors:  Lawrence J Brandt; Olga C Aroniadis; Mark Mellow; Amy Kanatzar; Colleen Kelly; Tina Park; Neil Stollman; Faith Rohlke; Christina Surawicz
Journal:  Am J Gastroenterol       Date:  2012-03-27       Impact factor: 10.864

6.  Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients.

Authors:  Christina Jorup-Rönström; Anders Håkanson; Staffan Sandell; Ove Edvinsson; Tore Midtvedt; Anna-Karin Persson; Elisabeth Norin
Journal:  Scand J Gastroenterol       Date:  2012-04-02       Impact factor: 2.423

Review 7.  Treating Clostridium difficile infection with fecal microbiota transplantation.

Authors:  Johan S Bakken; Thomas Borody; Lawrence J Brandt; Joel V Brill; Daniel C Demarco; Marc Alaric Franzos; Colleen Kelly; Alexander Khoruts; Thomas Louie; Lawrence P Martinelli; Thomas A Moore; George Russell; Christina Surawicz
Journal:  Clin Gastroenterol Hepatol       Date:  2011-08-24       Impact factor: 11.382

8.  Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.

Authors:  Oliver A Cornely; Derrick W Crook; Roberto Esposito; André Poirier; Michael S Somero; Karl Weiss; Pamela Sears; Sherwood Gorbach
Journal:  Lancet Infect Dis       Date:  2012-02-08       Impact factor: 25.071

Review 9.  Fecal bacteriotherapy for recurrent Clostridium difficile infection.

Authors:  Johan S Bakken
Journal:  Anaerobe       Date:  2009-09-22       Impact factor: 3.331

10.  Fecal microbiota transplant for recurrent Clostridium difficile infection: Mayo Clinic in Arizona experience.

Authors:  Neal C Patel; Cheryl L Griesbach; John K DiBaise; Robert Orenstein
Journal:  Mayo Clin Proc       Date:  2013-08       Impact factor: 7.616

View more
  14 in total

1.  Seeking safe stool: Canada needs a universal donor model.

Authors:  Carolyn Edelstein; Jamie R Daw; Zain Kassam
Journal:  CMAJ       Date:  2015-12-22       Impact factor: 8.262

Review 2.  Recurrent Clostridium difficile infection and the microbiome.

Authors:  Rowena Almeida; Teklu Gerbaba; Elaine O Petrof
Journal:  J Gastroenterol       Date:  2015-07-08       Impact factor: 7.527

3.  Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: A promising treatment approach.

Authors:  Monika Fischer; Brian Sipe; Yao-Wen Cheng; Emmalee Phelps; Nicholas Rogers; Sashidhar Sagi; Matthew Bohm; Huiping Xu; Zain Kassam
Journal:  Gut Microbes       Date:  2016-12-21

4.  Update on Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Disease.

Authors:  Paul Moayyedi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

Review 5.  Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection.

Authors:  Fawziah Marra; Karen Ng
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

Review 6.  Ulcerative Colitis: Update on Medical Management.

Authors:  Heba N Iskandar; Tanvi Dhere; Francis A Farraye
Journal:  Curr Gastroenterol Rep       Date:  2015-11

Review 7.  Fecal Microbiota Therapy for Clostridium difficile Infection: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2016-07-01

8.  A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection.

Authors:  Theodore Rokkas; Javier P Gisbert; Antonio Gasbarrini; Georgina L Hold; Herbert Tilg; Peter Malfertheiner; Francis Megraud; Colm O'Morain
Journal:  United European Gastroenterol J       Date:  2019-05-27       Impact factor: 4.623

9.  Humanized microbiota mice as a model of recurrent Clostridium difficile disease.

Authors:  James Collins; Jennifer M Auchtung; Laura Schaefer; Kathryn A Eaton; Robert A Britton
Journal:  Microbiome       Date:  2015-08-20       Impact factor: 14.650

Review 10.  Human Gut Microbiota: Toward an Ecology of Disease.

Authors:  Susannah Selber-Hnatiw; Belise Rukundo; Masoumeh Ahmadi; Hayfa Akoubi; Hend Al-Bizri; Adelekan F Aliu; Tanyi U Ambeaghen; Lilit Avetisyan; Irmak Bahar; Alexandra Baird; Fatema Begum; Hélène Ben Soussan; Virginie Blondeau-Éthier; Roxane Bordaries; Helene Bramwell; Alicia Briggs; Richard Bui; Matthew Carnevale; Marisa Chancharoen; Talia Chevassus; Jin H Choi; Karyne Coulombe; Florence Couvrette; Samantha D'Abreau; Meghan Davies; Marie-Pier Desbiens; Tamara Di Maulo; Sean-Anthony Di Paolo; Sabrina Do Ponte; Priscyla Dos Santos Ribeiro; Laure-Anne Dubuc-Kanary; Paola K Duncan; Frédérique Dupuis; Sara El-Nounou; Christina N Eyangos; Natasha K Ferguson; Nancy R Flores-Chinchilla; Tanya Fotakis; Mariam Gado Oumarou H D; Metodi Georgiev; Seyedehnazanin Ghiassy; Natalija Glibetic; Julien Grégoire Bouchard; Tazkia Hassan; Iman Huseen; Marlon-Francis Ibuna Quilatan; Tania Iozzo; Safina Islam; Dilan B Jaunky; Aniththa Jeyasegaram; Marc-André Johnston; Matthew R Kahler; Kiranpreet Kaler; Cedric Kamani; Hessam Karimian Rad; Elisavet Konidis; Filip Konieczny; Sandra Kurianowicz; Philippe Lamothe; Karina Legros; Sebastien Leroux; Jun Li; Monica E Lozano Rodriguez; Sean Luponio-Yoffe; Yara Maalouf; Jessica Mantha; Melissa McCormick; Pamela Mondragon; Thivaedee Narayana; Elizaveta Neretin; Thi T T Nguyen; Ian Niu; Romeo B Nkemazem; Martin O'Donovan; Matthew Oueis; Stevens Paquette; Nehal Patel; Emily Pecsi; Jackie Peters; Annie Pettorelli; Cassandra Poirier; Victoria R Pompa; Harshvardhan Rajen; Reginald-Olivier Ralph; Josué Rosales-Vasquez; Daria Rubinshtein; Surya Sakr; Mohammad S Sebai; Lisa Serravalle; Fily Sidibe; Ahnjana Sinnathurai; Dominique Soho; Adithi Sundarakrishnan; Veronika Svistkova; Tsolaye E Ugbeye; Megan S Vasconcelos; Michael Vincelli; Olga Voitovich; Pamela Vrabel; Lu Wang; Maryse Wasfi; Cong Y Zha; Chiara Gamberi
Journal:  Front Microbiol       Date:  2017-07-17       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.